Acadia Healthcare
ACHC
29.23
+0.19
+0.65%
Acadia Healthcare
US · ACHC
#2588 by market cap
Listed 1970
29.23
+0.19
+0.65%
Live - 5344 symbols - heartbeat 200s ago
· 2026-10-08 04:07
Pre-market
29.16
-0.23%
After-hours
29.23
0.00%
- Market cap
- 2.72B
- P/E (TTM)i
- -2.35
- P/Bi
- 1.38
- EPSi
- -12.16
- Div yieldi
- 0.00%
- 52W posi
- 73%
Reader sentiment
Are you bullish or bearish on ACHC?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.18, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +5.04% YoY
Margins
- Gross margin
- 96.44%
- Operating margin
- 11.71%
- Net margin
- -33.29%
Key ratios & quality
- Enterprise valuei
- 5.11B
- Altman Z-Scorei
- 1.18
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.90B | 2.01B | 2.09B | 2.31B | 2.61B | 2.93B | 3.15B | 3.31B |
| Gross profit | 1.82B | 1.92B | 2.00B | 2.22B | 2.51B | 2.82B | 3.04B | 3.19B |
| Selling & admin expenses | 1.19B | 1.26B | 1.31B | 1.42B | 1.60B | 1.79B | 1.93B | 2.06B |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 305.54M | 314.09M | 365.61M | 414.47M | 467.70M | 513.02M | 522.28M | 387.97M |
| Pretax profit | 67.40M | 78.40M | 183.80M | 275.76M | 374.14M | -25.36M | 341.88M | -1.07B |
| Tax | 9.91M | 25.09M | 40.61M | 67.56M | 94.11M | -9.70M | 77.40M | 25.98M |
| Net profit | -175.49M | 110.12M | -669.20M | 195.56M | 280.03M | -15.66M | 264.48M | -1.09B |
| Basic EPS | -2 | 1 | -8 | 2 | 3 | 0 | 3 | -12 |
| Diluted EPS | -2.01 | 1.24 | -7.65 | 2.10 | 2.98 | -0.24 | 2.78 | -12.16 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 770.51M | 869.23M | 851.57M | 821.46M | 828.80M | 865.84M |
| Gross profit | 742.16M | 840.70M | 821.16M | 790.70M | 799.31M | 835.64M |
| Selling & admin expenses | 502.63M | 514.99M | 525.38M | 521.20M | 531.97M | 541.70M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 78.50M | 142.30M | 119.52M | 47.64M | 83.84M | 87.77M |
| Pretax profit | 13.47M | 50.00M | 39.99M | -1.17B | 10.96M | 22.01M |
| Tax | 4.40M | 12.07M | 1.67M | 7.84M | 6.50M | 9.75M |
| Net profit | 9.06M | 37.94M | 38.32M | -1.18B | 4.46M | 12.26M |
| Basic EPS | 0 | 0 | 0 | -13 | 0 | 0 |
| Diluted EPS | 0.09 | 0.33 | 0.40 | -13.02 | 0.05 | 0.12 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 450.42M | 542.21M | 2.52B | 495.03M | 506.13M | 596.00M | 577.49M | 814.14M |
| Cash & ST investments | 50.51M | 99.54M | 378.70M | 133.81M | 97.65M | 100.07M | 76.31M | 133.24M |
| Inventory | 5.06M | 4.08M | 4.85M | 4.79M | 5.09M | 5.30M | 5.65M | 5.69M |
| Total assets | 6.17B | 6.88B | 6.50B | 4.77B | 4.99B | 5.36B | 5.96B | 5.53B |
| Total current liabilities | 416.38M | 463.58M | 1.31B | 404.86M | 388.33M | 885.78M | 577.92M | 525.19M |
| Short-term debt | 34.11M | 65.56M | 204.58M | 42.93M | 48.70M | 56.48M | 103.37M | 50.69M |
| Long-term debt | 3.16B | 3.11B | 2.97B | 1.48B | 1.36B | 1.34B | 1.88B | 2.47B |
| Total liabilities | 3,839,197,000.00 | 4,373,761,000.00 | 4,599,906,000.00 | 2,185,201,000.00 | 2,086,917,000.00 | 2,471,181,000.00 | 2,766,084,000.00 | 3,386,896,000.00 |
| Total equity | 2.33B | 2.51B | 1.90B | 2.58B | 2.90B | 2.89B | 3.19B | 2.14B |
| Retained earnings | 252.82M | 361.75M | -310.39M | -119.75M | 153.39M | 131.72M | 387.33M | -765.84M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 638.95M | 691.56M | 747.96M | 814.14M | 837.20M | 845.29M |
| Cash & ST investments | 91.24M | 131.42M | 118.69M | 133.24M | 158.47M | 171.29M |
| Inventory | 5.71M | 5.82M | 6.25M | 5.69M | 5.93M | 6.26M |
| Total assets | 6.15B | 6.31B | 6.41B | 5.53B | 5.55B | 5.55B |
| Total current liabilities | 473.35M | 523.71M | 517.92M | 525.19M | 489.36M | 537.58M |
| Short-term debt | 42.16M | 43.99M | 46.94M | 50.69M | 54.32M | 54.34M |
| Long-term debt | 2.18B | 2.25B | 2.28B | 2.47B | 2.49B | 2.38B |
| Total liabilities | 2,973,620,000.00 | 3,084,830,000.00 | 3,122,811,000.00 | 3,386,896,000.00 | 3,378,191,000.00 | 3,354,478,000.00 |
| Total equity | 3.17B | 3.22B | 3.29B | 2.14B | 2.17B | 2.19B |
| Retained earnings | 348.45M | 375.42M | 411.67M | -765.84M | -761.74M | -750.81M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 414.08M | 332.90M | 658.81M | 374.48M | 380.57M | 462.34M | 129.69M | 131.90M |
| Depreciation & amortization | 80.34M | 87.92M | 95.26M | 106.72M | 117.77M | 132.35M | 149.60M | 189.25M |
| Free cash flow | 160.89M | 100.23M | 433.84M | 129.67M | 84.42M | 38.21M | -560.69M | -439.91M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -3.41M | -- | -- | -- | -- | 0 | 0 | -50.03M |
| Ending cash balance | 30.19M | 99.54M | 378.70M | 133.81M | 97.65M | 100.07M | 76.31M | 133.24M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 11.48M | 133.50M | 73.21M | -86.29M | 61.53M | 162.07M |
| Depreciation & amortization | 47.03M | 49.00M | 47.47M | 45.75M | 52.43M | 50.43M |
| Free cash flow | -163.15M | -34.24M | -63.03M | -179.48M | -15.03M | 123.51M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -46.88M | -3.15M | 0 | 0 | 0 | 0 |
| Ending cash balance | 91.24M | 131.42M | 118.69M | 133.24M | 158.47M | 171.29M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -7.16 | 4.50 | -30.52 | 8.63 | 10.25 | -0.77 | 8.73 | -43.91 |
| ROA %i | -2.79 | 1.67 | -10.05 | 3.38 | 5.60 | -0.42 | 4.52 | -19.20 |
| ROIC %i | -0.71 | 4.45 | -9.67 | 5.34 | 7.66 | 0.67 | 7.32 | -20.37 |
| 5-year avg ROE %i | 4.51 | 2.97 | -4.89 | -3.22 | -2.86 | -1.58 | -0.74 | -3.42 |
| EBIT margin %i | 0.55 | 10.40 | 16.36 | 15.24 | 17.01 | 1.94 | 14.53 | -27.99 |
| FCF / sales %i | 2.41 | 1.55 | 21.16 | 5.60 | 3.23 | 1.30 | -- | -- |
| Current ratioi | 1.08 | 1.17 | 1.93 | 1.22 | 1.30 | 0.67 | 1.00 | 1.55 |
| Quick ratioi | 0.97 | 0.91 | 0.52 | 1.08 | 1.16 | 0.60 | 0.86 | 1.29 |
| Debt / assetsi | 51.74 | 47.34 | 50.12 | 34.36 | 30.67 | 27.99 | 35.01 | 47.84 |
| LT debt / equityi | 135.40 | 127.37 | 160.73 | 63.38 | 52.65 | 51.88 | 64.48 | 133.07 |
| Interest coveragei | 0.09 | 1.73 | 2.16 | 4.58 | 6.36 | 0.69 | 3.94 | -6.68 |
| Revenue CAGR (3Y) %i | 2.01 | -10.60 | -9.68 | 6.71 | 9.13 | 11.91 | 10.87 | 8.27 |
| Net income CAGR (3Y) %i | -- | 160.76 | -- | -- | 35.86 | -- | 10.27 | -- |
| FCF CAGR (3Y) %i | -- | 22.89 | 51.24 | -6.94 | -5.56 | -55.51 | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 6.35 | 4.62 | 3.49 | -43.91 | -44.28 | -44.54 |
| ROA %i | 3.22 | 2.32 | 1.75 | -19.20 | -18.93 | -19.00 |
| ROIC %i | 5.43 | 4.50 | 4.11 | -20.37 | -20.37 | -20.70 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 11.88 | 10.04 | 8.34 | -27.99 | -27.30 | -28.07 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 1.35 | 1.32 | 1.44 | 1.55 | 1.71 | 1.57 |
| Quick ratioi | 1.18 | 1.17 | 1.20 | 1.29 | 1.44 | 1.35 |
| Debt / assetsi | 37.86 | 37.82 | 37.85 | 47.84 | 48.14 | 46.25 |
| LT debt / equityi | 75.15 | 76.08 | 76.28 | 133.07 | 133.57 | 126.87 |
| Interest coveragei | 3.17 | 2.61 | 2.08 | -6.68 | -6.22 | -6.26 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Behavioral healthcare services100.00%
Quote time 2026-10-08 04:07:19 · For reference only, not investment advice and not tailored to your situation.